Scarica l'app Stockscreener
42.15
2.26%
0.93
Dopo l'orario di chiusura:
41.31
-0.84
-1.99%
Xenon Pharmaceuticals Inc Borsa (XENE) Ultime notizie
JPMorgan reiterates Overweight rating on Xenon Pharmaceuticals stock By Investing.com - Investing.com UK
XENE: JP Morgan Raises Xenon Pharmaceuticals' Price Target | XEN - GuruFocus
Can Xenon Pharmaceuticals Inc. stock deliver surprise earnings beatJuly 2025 Institutional & Daily Risk Controlled Trade Plans - ulpravda.ru
Is Xenon Pharmaceuticals Inc. stock supported by strong cash flowsMarket Sentiment Summary & Smart Allocation Stock Reports - ulpravda.ru
Can Xenon Pharmaceuticals Inc. stock maintain operating marginsQuarterly Trade Review & Stepwise Trade Execution Plans - ulpravda.ru
How rising interest rates impact Xenon Pharmaceuticals Inc. stockLong-Term Growth Stocks & We Spotted the Next Tesla – See Inside - ulpravda.ru
Why Xenon Pharmaceuticals Inc. stock remains undervaluedForecast Cut & Free Reliable Trade Execution Plans - ulpravda.ru
Why Xenon Pharmaceuticals stock is down today as JPM Healthcare Conference nears - TechStock²
Xenon Pharmaceuticals (NASDAQ:XENE) Hits New 12-Month HighTime to Buy? - MarketBeat
Xenon to Showcase Neuroscience Pipeline at J.P. Morgan Healthcare Conference - TipRanks
Cantor Fitzgerald raises Xenon Pharmaceuticals stock price target to $55 By Investing.com - Investing.com UK
Xenon Pharmaceuticals Inc. to Present at 44th Annual J.P. Morgan Healthcare Conference in January 2026 - Quiver Quantitative
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference - Bluefield Daily Telegraph
(XENE) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Xenon Pharmaceuticals (NASDAQ:XENE) CEO Ian Mortimer Sells 40,000 Shares - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Up 3.8% – Should You Buy? - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Trading 3.8% HigherHere's Why - MarketBeat
Analysts Conflicted on These Healthcare Names: Lifecore Biomedical (LFCR) and Xenon (XENE) - The Globe and Mail
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Novavax (NVAX), Xenon (XENE) and Biohaven Ltd. (BHVN) - The Globe and Mail
Commit To Purchase Xenon Pharmaceuticals At $32.50, Earn 25.8% Annualized Using Options - Nasdaq
Xenon announces new data on 48-month azetukalner OLE study data - MSN
Stifel reiterates Buy rating on Xenon Pharmaceuticals stock amid competitor setback - Investing.com Canada
Biohaven Misses The Mark In Depression Trial, Stock Falls - Sahm
Traders Purchase High Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE) - MarketBeat
Why (XENE) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Pullback Watch: How rising interest rates impact Xenon Pharmaceuticals Inc. stockMarket Sentiment Report & Growth Focused Stock Pick Reports - Улправда
Analysts Offer Insights on Healthcare Companies: Xenon (XENE) and 4D Molecular Therapeutics (FDMT) - The Globe and Mail
Returns Recap: Why Xenon Pharmaceuticals Inc. stock remains undervaluedJuly 2025 PostEarnings & Capital Efficient Trading Techniques - Улправда
Will Xenon Pharmaceuticals Inc. stock outperform tech sector in 20252025 Price Targets & Long Hold Capital Preservation Plans - Улправда
Can Xenon Pharmaceuticals Inc. stock resist sector downturns2025 Price Momentum & Precise Entry and Exit Recommendations - Улправда
Xenon Pharmaceuticals Inc (XENE)’s stock price in review: A technical analysis - uspostnews.com
Is Xenon Pharmaceuticals Inc. stock attractive for passive investorsPortfolio Update Report & AI Powered Buy and Sell Recommendations - Улправда
Xenon Pharmaceuticals: Derisked Pipeline Ahead Of Critical 2026 Phase 3 Readout (NASDAQ:XENE) - Seeking Alpha
Xenon Pharmaceuticals Inc. $XENE is Braidwell LP's 7th Largest Position - MarketBeat
Xenon Pharmaceuticals Inc. (XENE) Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch PreparationSlideshow (NASDAQ:XENE) 2025-12-12 - Seeking Alpha
Xenon Pharmaceuticals (NASDAQ:XENE) Given New $48.00 Price Target at Wells Fargo & Company - Defense World
Wells Fargo Maintains Xenon Pharmaceuticals (XENE) Overweight Recommendation - Nasdaq
XENE Stock Update: Wells Fargo Raises Price Target to $48 | XENE - GuruFocus
Russell Investments Group Ltd. Decreases Holdings in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - MarketBeat
Xenon projects top line X-TOLE2 data in early 2026 as enrollment surpasses target, expanding late-stage pipeline - MSN
Transcript : Xenon Pharmaceuticals Inc.Special Call - marketscreener.com
Ian Mortimer Sells 10,830 Shares of Xenon Pharmaceuticals (NASDAQ:XENE) Stock - MarketBeat
Insider Selling: Xenon Pharmaceuticals (NASDAQ:XENE) CEO Sells 14,375 Shares of Stock - MarketBeat
Ian Mortimer, Xenon Pharma CEO, sells $1.14m in shares By Investing.com - Investing.com South Africa
Ian Mortimer, Xenon Pharma CEO, sells $1.14m in shares - Investing.com
Xenon Pharmaceuticals President & CEO Ian Mortimer Sells Shares - TradingView — Track All Markets
Xenon Pharmaceuticals unveils promising long-term epilepsy treatment data - MSN
CEO Mortimer Files To Sell 10,830 Of Xenon Pharmaceuticals Inc [XENE] - TradingView — Track All Markets
Marshall Wace LLP Acquires 262,109 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):